Serum ganciclovir drug exposure in children receiving standard ganciclovir dosing.

ABSTRACT: Intravenous ganciclovir (GCV) is used for the treatment of cytomegalovirus (CMV) infection in immunocompromised children. Although the therapeutic target for treatment is unclear, studies have shown a serum area under the concentration-time curve (AUC_24h) ≥40 mg/L·h correlates with effective CMV prevention. This study aimed to externally validate existing GCV population pharmacokinetic (PopPK) models and develop a model if needed and evaluate the serum AUC_24h achieved with standard GCV dosing and propose an optimized dosing strategy for immunocompromised children. Ganciclovir drug monitoring data from two pediatric hospitals were retrospectively collected, and published pediatric PopPK models were externally validated. The population AUC_24h with standard GC

SUBMITTER: Yang W 

PROVIDER: S-EPMC11459965 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature